Archive
1319 articles, sorted by publication time.
People with Alzheimer’s disease can differ in their cognitive decline and emotional changes. Researchers are combining large-scale brain tissue data with graph neural networks to identify cellular clues behind these differences, offering a new route for exploring therapeutic targets.
In a small trial involving nine adults, foveal schisis remained closed in seven treated eyes, with some eyes also showing improvements in light sensitivity and visual acuity. These findings offer a potential treatment lead for X-linked retinoschisis, but whether the benefits can consistently extend to more patients awaits confirmation in the ongoing Phase 3 trial.
Single-lead ECGs predicted left ventricular function nearly as well as 12-lead ECGs, offering new clues for home monitoring; but moving from signal recognition to reliable clinical alerts still requires validation.
A trial involving 44 adolescents has brought a drug originally used in adults to regulate heart muscle contraction into pediatric care. The study showed reduced obstruction to blood flow out of the heart, but long-term benefits and safety require further follow-up, and the heart failure warning and treatment monitoring requirements remain in place.
Candel’s new analysis links a lower risk of recurrence with immune signals in tumor tissue and blood, offering biological clues for combining viral therapy with radiation therapy; however, the small blood study and exploratory findings are not yet sufficient to demonstrate systemic protection against cancer.
Being able to read a few more lines in dim light may represent a meaningful change for people whose vision is gradually deteriorating. The pivotal trial of laru-zova met its primary efficacy endpoint, but how long the improvement lasts and how to weigh the surgical risks remain important questions on the path to approval.
Antibodies must clear multiple hurdles to move from binding a target to being suitable for further development. Xaira has released experimental results from two programs, demonstrating the feasibility of AI design while revealing the prerequisites behind the speed and the limits of the evidence.
uRARE-seq demonstrated high detection sensitivity in a study and explored immune and proliferation signals in urine for clues to treatment selection; whether it can reduce the burden of repeated examinations and improve treatment outcomes still requires prospective validation.
Finding clues to small-molecule binding from protein sequences could offer another route for drug targets that are difficult to characterize structurally. The newly opened platform can screen up to ten thousand compounds at a time, but its impressive STAT6 test results still await broader independent validation.
Enabling cells in the body to produce therapeutic molecules that engage T cells is the approach ABO2203 seeks to establish. The cross-border licensing deal also includes options on other RNA programs, but the potential total of nearly $7.8 billion depends on subsequent development and commercial outcomes.
The AUTUS valve can be resized after implantation using a balloon catheter, offering the possibility of fewer repeat open-heart surgeries for children with congenital heart disease. However, only two patients have undergone expansion so far, and whether the valve can maintain its function over the long term remains to be verified.
Tumor tissue removed during surgery may offer clues for subsequent treatment. An analysis across 26 centers shows outstanding long-term survival among patients who respond well to neoadjuvant immunotherapy and suggests a research direction for reducing postoperative medication; however, prospective trials are still needed to confirm who can safely receive less treatment.